TX-MAVENIR
11.6.2024 15:01:33 CEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announced that it has pioneered a breakthrough Operations Co-Pilot that harnesses the power of generative AI (GenAI) to improve service-level agreements (SLAs) and optimize operational efficiency for communications service providers (CSPs). The innovation, which has been developed in collaboration with NVIDIA and Amazon Web Services (AWS), showcases the potential of GenAI to effectively define a Service Assurance AI/Ops Platform – reducing the burden on operations, support and maintenance teams and enhancing their ability to meet SLAs.
Mavenir’s Operations Co-Pilot for RAN Service Assurance (RSA) automates network troubleshooting, enabling mobile network operators to rapidly and accurately anticipate network issues and address detected network impairments before they become critical. The Operations Co-Pilot significantly reduces manual debugging effort, development and maintenance lead times to enhance IT operations, service availability and delivery for increasingly complex mobile networks.
Utilizing the power of GenAI with large language models (LLMs) trained on detailed key performance indicators (KPIs), counters, logs and traces from network infrastructure, Mavenir, together with NVIDIA and AWS, is creating a suite of Operations Co-Pilot solutions that will transform the operations management of telecom networks through intelligent automation. This new framework – built on NVIDIA Tensor Core GPUs and the NVIDIA AI Enterprise software platform for generative AI running on AWS – leverages Mavenir’s Open RAN architecture to provide accessibility into multiple open interfaces that can deliver the data needed to train and optimize domain-specific telecom LLMs.
Mavenir’s Chief Technology and Strategy Officer Bejoy Pankajakshan commented: “Our new Operations Co-Pilot framework has the potential to be a game-changer for operators, delivering a wealth of fault prediction and root cause analysis capabilities with AI-powered accuracy and speed. This industry-first solution is built on the transformative foundation of NVIDIA GPUs operating on AWS and enabled by Mavenir data, which can be accessed via numerous interfaces in the Open RAN and in the Packet Core for complete end-to-end visibility.”
He added: “The three key use cases of Core Dump Analysis, Log Similarity Search feature and Log Anomaly Detection can be used together to maximize the automated efficiency gains. Combining information from these trained LLMs will provide broader and deeper coverage of all fault and anomaly scenarios, enabling very early prediction of potential problems in the network. Moreover, as these solutions evolve, the models have the ability to continuously learn and optimize based on user feedback and iterative training with further logs, KPIs and traces, promising even greater gains.”
“In today’s fast-paced digital landscape, generative AI is a force multiplier for enterprises everywhere,” said Chris Penrose, global head of business development for telco at NVIDIA. “Mavenir’s framework, built on the NVIDIA AI Enterprise platform for streamlining the development and deployment of AI, will unlock a new level of operational efficiency for communications service providers.”
Notes to editors: Watch the video overview: Mavenir’s Operations Co-Pilot for RAN Service Assurance (RSA)
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610302138/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
